Silas Inman | Authors

Articles

Phase 3 Study Explores Pamrevlumab for Unresectable LAPC

February 17, 2021

The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.